Immutep (NASDAQ:IMMP) Shares Down 4.6% - Here's What Happened

Immutep Limited (NASDAQ:IMMP - Get Free Report)'s share price traded down 4.6% during mid-day trading on Monday . The company traded as low as $2.00 and last traded at $2.08. 226,482 shares traded hands during mid-day trading, an increase of 5% from the average session volume of 214,748 shares. The stock had previously closed at $2.18.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their target price on shares of Immutep from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, November 15th.

Immutep Stock Down 4.6 %

The firm's fifty day simple moving average is $1.99 and its 200 day simple moving average is $2.19. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.

Institutional Trading of Immutep

Several hedge funds have recently made changes to their positions in IMMP. XTX Topco Ltd purchased a new stake in Immutep in the 2nd quarter worth about $26,000. XY Capital Ltd bought a new position in shares of Immutep during the second quarter valued at approximately $105,000. Finally, Meridian Wealth Management LLC boosted its stake in shares of Immutep by 4.5% during the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company's stock valued at $881,000 after purchasing an additional 17,250 shares in the last quarter. 2.32% of the stock is currently owned by hedge funds and other institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.